A paradigm shift to prevent HIV drug resistance

PLoS Medicine

Volumn 5, Issue 5, 2008, Pages 0695-0696

  Bangsberg, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; VIRUS RNA;

CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOBILE PHONE; MONITORING; PHARMACY; REVIEW; VIROLOGY; VIRUS LOAD; ANTIVIRAL RESISTANCE; CD4+ T LYMPHOCYTE; CYTOLOGY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; METHODOLOGY; NOTE; PATHOLOGY; PATIENT COMPLIANCE; PHYSIOLOGIC MONITORING; TREATMENT OUTCOME;

ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; MONITORING, PHYSIOLOGIC; PATIENT COMPLIANCE; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 44449097190     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050111     Document Type: Review

References (16)

1. World Health Organization (2007) Management of HIV Infection and Antiretroviral Therapy in Adults and Adolescents. A Clinical Manual. Available: http://www.searo.who.int/LinkFiles/ Publications_Management_HIV_infection_antiretroviral_therapy_adults_adolescents. pdf. Accessed 8 April 2008.
2. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, et al. (2007) HIV viral load monitoring in resource-limited regions: Optional or necessary? Clin Infect Dis 44: 128-134.
3. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, et al. (2008) Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 5: e109. doi:10.1371/journal.pmed.0050109
4. Mannheimer S, Friedland G, Matts J, Child C, Chesney M (2002) The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 34: 1115-1121.
5. Liu H, Miller LG, Hays RD, Golin CE, Wu T, et al. (2006) Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr 41: 315-322.
6. Parruti G, Manzoli L, Toro PM, D'Amico G, Rotolo S, et al. (2006) Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: predictors and impact on virologic response and relapse. AIDS Patient Care STDS 20: 48-56.
7. Bangsberg DR (2008) Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis 197: S272-S278.
8. Gross R, Yip B, Lo Re V 3rd, Wood E, Alexander CS, et al. (2006) A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis 194: 1108-1114.
9. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, et al. (2003) Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med 139: 810-816.
10. Harrigan R, Dong W, Alexander C, Yip B, Ting L, et al. (2003) The association between drug resistance and adherence determined by two independent methods in a large cohort of drug naive individuals starting triple therapy [abstract LB12]. Second International Conference on HIV Treatment and Pathogenesis; 13-17 July 2003; Paris, France.
11. Hogg R, Heath K, Bangsberg DR, Yip B, Press N, et al. (2002) Intermittent use of triple combination therapy is predictive of mortality at baseline and after one year of follow-up AIDS. AIDS 16: 1051-1058.
12. Parienti J, Massari V, Descamps D, Vabret A, Bouvet E, et al. (2004) Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine or efavirenz-based antiretroviral therapy. Clin Infect Dis 38: 1311-1316.
13. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, et al. (2007) Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 21: 965-971.
14. Ruskin P, Van der Wende J, Clark C, Fenton J, Deveau J, et al. (2003) Feasibility of using the MedeMonitor system in the treatment of schizophrenia: A pilot study. Drug Inf J 37: 283-291.
15. Ybarra ML, Bull SS (2007) Current trends in Internet- and cell phone-based HIV prevention and intervention programs. Curr HIV/AIDS Rep 4: 201-207.
16. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, et al. (2008) Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: A computer simulation model. Lancet 371: 1443-1451.